• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

    2.845 -0.025 (-0.87%)
    Streaming Delayed Price Updated: 3:44 PM EST, Dec 26, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 6,963,869
    Open 2.920
    Bid (Size) 2.840 (8,300)
    Ask (Size) 2.850 (9,200)
    Prev. Close 2.870
    Today's Range 2.820 - 2.990
    52wk Range 1.639 - 8.150
    Shares Outstanding 305,252,194
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    2 Stocks That Could Soar by 52% and 282%, According to Wall Street ↗
    This juicy upside potential comes at a cost. 
    Via The Motley Fool

    Performance

    YTD
    -63.5%
    -63.5%
    1 Month
    +14.7%
    +14.7%
    3 Month
    +40.8%
    +40.8%
    6 Month
    +63.5%
    +63.5%
    1 Year
    -62.6%
    -62.6%

    More News

    Read More
    News headline image
    Iovance (IOVA) Q3 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    Biotech Valuations Rise as New Clinical Platforms Show Progress
    Via Investor Brand Network
    Why Are IOVA Shares Rising Today? ↗
    Via Stocktwits
    News headline image
    Earnings Scheduled For November 6, 2025 ↗
    Via Benzinga
    News headline image
    Biotech Valuations Rise as New Clinical Platforms Show Progress
    From BioMedWire
    Via GlobeNewswire
    News headline image
    Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Down 75% in 12 Months, Can Iovance Biotherapeutics Stock Turn Things Around? ↗
    Via The Motley Fool
    News headline image
    2 Small-Cap Stocks With Far More Upside Than Any "Magnificent Seven" Stock, According to Wall Street ↗
    Via The Motley Fool
    News headline image
    Top movers in Thursday's session ↗
    Via Chartmill
    News headline image
    Synergy CHC (NASDAQ: SNYR) Expands FOCUSfactor® Beverage Rollout – Eyes $100M+ in 2026
    Via AB Newswire
    News headline image
    Top stock movements in today's session. ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Thursday's Intraday Session ↗
    Via Benzinga
    News headline image
    Gapping stocks in Thursday's session ↗
    Via Chartmill
    News headline image
    Iovance Biotherapeutics Highlights Business Achievements, Pipeline Milestones, and Third Quarter 2025 Results
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Examining the Future: Iovance Biotherapeutics's Earnings Outlook ↗
    Via Benzinga
    News headline image
    Iovance Biotherapeutics Reports Potential Best-in-Class Clinical Data for Lifileucel TIL Cell Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC)
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability
    Via Investor Brand Network
    News headline image
    Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability
    Via FinancialNewsMedia
    News headline image
    IOVANCE INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Continues Investigation on Behalf of Long-Term Iovance, Inc. Stockholders
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    Iovance Biotherapeutics to Host Third Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, November 6, 2025
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Adaptimmune Plunges After Announcing Nasdaq Delisting Amidst Compliance Failures and Cost-Cutting Measures
    Via MarketMinute
    Topics Initial Public Offering Regulatory Compliance Workforce
    News headline image
    Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Turnstone Biologics: A $100 Dream Collides with a $0.34 Reality
    Via MarketMinute
    Topics Intellectual Property Workforce

    Frequently Asked Questions

    Is Iovance Biotherapeutics, Inc. - Common Stock publicly traded?
    Yes, Iovance Biotherapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Iovance Biotherapeutics, Inc. - Common Stock trade on?
    Iovance Biotherapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Iovance Biotherapeutics, Inc. - Common Stock?
    The ticker symbol for Iovance Biotherapeutics, Inc. - Common Stock is IOVA on the Nasdaq Stock Market
    What is the current price of Iovance Biotherapeutics, Inc. - Common Stock?
    The current price of Iovance Biotherapeutics, Inc. - Common Stock is 2.845
    When was Iovance Biotherapeutics, Inc. - Common Stock last traded?
    The last trade of Iovance Biotherapeutics, Inc. - Common Stock was at 12/26/25 03:44 PM ET
    What is the market capitalization of Iovance Biotherapeutics, Inc. - Common Stock?
    The market capitalization of Iovance Biotherapeutics, Inc. - Common Stock is 868.44M
    How many shares of Iovance Biotherapeutics, Inc. - Common Stock are outstanding?
    Iovance Biotherapeutics, Inc. - Common Stock has 868M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.